Cantor Fitzgerald Reiterates “Overweight” Rating for COMPASS Pathways (NASDAQ:CMPS)

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report released on Friday,Benzinga reports.

CMPS has been the topic of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Stock Performance

CMPS opened at $2.94 on Friday. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a 12-month low of $2.88 and a 12-month high of $10.31. The business has a 50 day moving average of $3.86 and a 200-day moving average of $4.72. The stock has a market cap of $272.46 million, a price-to-earnings ratio of -1.34 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities research analysts expect that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Trading of COMPASS Pathways

Several large investors have recently modified their holdings of CMPS. RTW Investments LP bought a new stake in COMPASS Pathways during the fourth quarter worth about $11,714,000. Altium Capital Management LLC acquired a new position in shares of COMPASS Pathways in the 4th quarter valued at approximately $5,384,000. Tang Capital Management LLC bought a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $3,780,000. Nantahala Capital Management LLC boosted its position in shares of COMPASS Pathways by 400.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $3,780,000 after acquiring an additional 800,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $2,458,000. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.